Antares pharma inc.

Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients.Jan 26, 2016 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ...

Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product …

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...Antares Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: x: Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule ...A copy of Antares Pharma, Inc.’s (the “Company”) updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.. The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall …Address Medical Inquiries to: Antares Pharma, Inc. Medical Communications 100 Princeton South, Suite 300 Ewing, NJ 08628, 1-855-Otrexup (1-855-687-3987) Nonclinical Toxicology. No Information provided. Use In Specific Populations Pregnancy Risk Summary. Based on published reports and methotrexate’s …

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and …

Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USA

On July 10, 2014, the district court denied the motion for preliminary injunction, finding that Antares failed to carry its burden of showing a likelihood of success on the merits with respect to the ’846 patent because claims 31, ANTARES PHARMA INC. v. MEDAC PHARMA INC. 5 34, 35, and 37, added during reissue, are likely invalid for violating ...Antares Pharma, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 41.56 million compared to USD 42.08 million a year ago. Net loss was USD 2.32 million compared to net income of USD 3.79 million a year ago. Basic loss per share from continuing operations …EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that …Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Source: Antares Pharma, Inc. March 29, 2022 07:00 ET A ntares P harma A nnounces FD A A pproval Of TLA N D O™, an Oral Treatment for Testosterone R epl acement Therapy C om m er c ial launc h ex pec ted in 2Q 2022 E W IN G , N .J ., M ar c h 29, 2022 ( G LO B E N E W S W IR E ) - - A ntar es P har m a, Inc . ( N A S D A Q : A T R S ) ( the “ C om …

May 24, 2022 · 24 May, 2022, 08:30 ET. SAN DIEGO, May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares ... Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Hayward Pool Products Inc. is a leading manufacturer and distributor of swimming pool equipment and supplies. With over 80 years of experience, the company has been at the forefront of innovation in the swimming pool industry.Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Jun 23, 2007 · Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...He concurrently serves as the Director of the Board of Swiss based subsidiaries of the US pharmaceutical company Antares Pharma Inc. (Nasdaq: ATRS). Further to these noteworthy contributions, he ...SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May ...Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA ...13. 4. 2022 ... Antares Pharma to be acquired by Halozyme in $960M deal ... Robert Apple, CEO of Antares Pharma. ... Antares, which was originally founded in Exton, ...Mar 29, 2022 · Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ... EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …

Reinventing the patient experience. The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes. 2015-2023. Halozyme, Inc.

He concurrently serves as the Director of the Board of Swiss based subsidiaries of the US pharmaceutical company Antares Pharma Inc. (Nasdaq: ATRS). Further to these noteworthy contributions, he ...

Antares Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: x: Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule ...Company profile page for Antares Pharma Inc including stock price, company news, press releases, executives, board members, and contact information ANTARES PHARMA, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to …Get directions. Antares Pharma Inc. | 5,022 followers on LinkedIn. Making Medicines Feel Better | About Antares Antares Pharma is a specialty pharmaceutical company that combines drug...18. 10. 2021 ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered ...15. 4. 2022 ... The Details: Laura Cooper was first to report that Halozyme Therapeutics Inc. was close to acquiring specialty pharmaceutical company Antares ...Home :: Antares Pharma. As of May 24, 2022 Halozyme completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable opportunities across the ENHANZE® and Antares’ auto injector technologies. View details here and send questions to [email protected]. Continue to Site. Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here.Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. On December 12, 2018, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) increased the size of the Board to eight members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Peter Greenleaf to the Board as a Class I Director. Mr. Greenleaf’s term will expire at the …View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and …On July 13, 2015, Antares Pharma, Inc. (“Antares”) entered into a Separation and Consulting Services Agreement (“Separation Agreement”) with Jennifer Evans Stacey, Senior Vice President, General Counsel, Human Resources and Secretary of Antares. Ms. Stacey’s last day of employment was July 13, 2015 (“Separation Date”).Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and …Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, manufacturing, and …Instagram:https://instagram. futures scalping strategytriple witchhow much does cytopoint costshel stock dividend Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results. Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... prologis newssqqq stock chart On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ... what's going on with amazon stock EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …A copy of Antares Pharma, Inc.’s (the “Company”) updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.. The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall …